ストックスクリーナーアプリを入手
32.88
0.12%
-0.04
Zenas Biopharma Inc (ZBIO) 最新ニュース
Zenas BioPharma (ZBIO) holder sells 673,755 shares in open-market trade - Stock Titan
Zenas BioPharma (ZBIO) affiliate plans August 2026 share sale - Stock Titan
Zenas BioPharma (ZBIO) Institutional Ownership 2026 - MarketBeat
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Zenas BioPharma hires receive stock awards vesting through 2030 - Stock Titan
HC Wainwright Predicts Higher Earnings for Zenas BioPharma - MarketBeat
SR One's stake in Zenas BioPharma (ZBIO) drops over 1 point without selling - Stock Titan
Morgan Stanley Maintains Zenas BioPharma(ZBIO.US) With Hold Rating, Raises Target Price to $32 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
ZBIO Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost Discipline for Clinical-Stage BiotechDividend Growth Analysis - Vinanet
Walleye Capital LLC Takes $5.31 Million Position in Zenas BioPharma, Inc. $ZBIO - MarketBeat
Zenas BioPharma's (ZBIO) Buy Rating Reaffirmed at Guggenheim - MarketBeat
Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush - MarketBeat
Zenas BioPharma (ZBIO) Is Down 9.2% After Wider Losses And Leadership ChangesWhat's Changed - simplywall.st
ZBIO SWOT Analysis: Financial Challenges and Strategic Opportuni - GuruFocus
Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results - MarketBeat
Zenas BioPharma Releases Q2 2026 Financial Results - AlphaStreet
Zenas BioPharma, Inc. Announces Chief Financial Officer Changes, Effective September 30, 2026 - marketscreener.com
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.6% on Disappointing Earnings - MarketBeat
Zenas BioPharma Q2 Results: EPS Misses, Sales Fall 95% - scanx.trade
Zenas BioPharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Zenas Biopharma Inc For: 13 August By Investing.com - Investing.com Canada
Zenas BioPharma's Q2 Net Loss Widens; CFO to Step Down - marketscreener.com
Earnings Flash (ZBIO) Zenas BioPharma Posts Q2 Loss $1.77 a Share, vs. FactSet Est of $1.12 Loss - marketscreener.com
Zenas BioPharma, Inc. 2026: Revenue $1M, Net income ($111.46M), EPS ($1.77) — 10-Q Summary - TradingView
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Earnings Flash (ZBIO) Zenas BioPharma, Inc. Reports Q2 Revenue $1.0M - marketscreener.com
Zenas BioPharma Reports $111.5 Million Second-Quarter Net Loss - Quiver Quantitative
Zenas BioPharma (ZBIO) Slides 3.55% to $31.29 as Biotech Sentiment Turns CautiousTotal Put Call - dars.gov.et
Zenas BioPharma (ZBIO) Edges Higher to $32.44 as Biotech Momentum BuildsMA Cross Alert - Vinanet
Zenas BioPharma (ZBIO) Rises 1.41% to $32.44 as Shares Hold Above Key SupportSynthetic Long - vinanet.vn
Zenas BioPharma (ZBIO) Holds Gains Above $32 as Bullish Momentum BuildsIndex Put Call - dars.gov.et
ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, In - The National Law Review
Zenas BioPharma, Inc. (ZBIO): Investor Outlook On A Potential 35% Upside - DirectorsTalk Interviews
Zenas BioPharma (ZBIO) Holds Firm at $32.43 as Biotech Sentiment SteadiesBreakout Trade - vinanet.vn
Zenas BioPharma (ZBIO) Edges Up 0.97% as Shares Hold Between Support and ResistanceCash Flow Strong Stocks - Vinanet
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, In - The National Law Review
Zenas BioPharma (ZBIO) Projected to Release Quarterly Earnings on Tuesday - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Levi & Korsinsky Urges Zenas BioPharma, Inc. (ZBIO) Shareholders to Act Before Lead Plaintiff Deadline June 16, 2025 - The National Law Review
Zenas Biopharma Inc (ZBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Exome Asset Management LLC Takes Position in Zenas BioPharma, Inc. $ZBIO - MarketBeat
Zenas Biopharma Inc (ZBIO) Balance Sheet - TradingKey
Zenas Biopharma Inc (ZBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zenas Biopharma Inc (ZBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Zenas Biopharma Inc (ZBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zenas BioPharma (NASDAQ:ZBIO) Trading 7.7% HigherStill a Buy? - MarketBeat
ZBIO|Zenas Biopharma Inc|Price:30.390|Chg%:-0.600 - TradingKey
Zenas Biopharma Inc (ZBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
ZBIO|Zenas Biopharma Inc|Price:31.830|Chg%:+1.330 - TradingKey
Securities Lawsuit Alert: Zenas BioPharma, Inc. (ZBIO) Investors - The National Law Review
125,232 Shares in Zenas BioPharma, Inc. $ZBIO Bought by Walleye Capital LLC - MarketBeat
Zenas BioPharma (ZBIO) Dips 2.7% as Resistance Holds: Key Levels to WatchSeasonality Effect - dars.gov.et
ZBIO6353884 Bond Profile — Key Metrics - TradingView
ZBIO6353884 Bond Risk Profile - TradingView
ZBIO6353884 Bond Coupon Profile — Rate & Payments - TradingView
Zenas BioPharma (ZBIO) Gains Nearly 4% as Biotech Momentum BuildsBackspread Trade - dars.gov.et
Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says - Moomoo
Zenas BioPharma Grants Inducement Stock Options and RSUs to New Employees - Quiver Quantitative
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):